Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vivos Therapeutics, Inc. - Common Stock (NQ:VVOS)

0.9801 -0.1099 (-10.08%)
Streaming Delayed Price Updated: 2:18 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vivos Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ:SDST)
Via ACCESS Newswire
News headline image
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
Via ACCESS Newswire
News headline image
New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX) on Bloomberg Television Tonight at 6:30 PM EST
Via ACCESS Newswire
News headline image
New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin America
Via ACCESS Newswire
Vivos Therapeutics Inc. (NASDAQ: VVOS) Near the Top of Equities by Percentage Gain on 11/29
Via Investor Brand Network
News headline image
New to The Street to Broadcast Show #726 on Bloomberg at 6:30 PM EST Featuring Vivos Therapeutics (NASDAQ:VVOS), Aeries Technology (NASDAQ:AERT), Virtuix Holdings (NASDAQ:VTIX), and Stardust Power (NASDAQ:SDST)
Via ACCESS Newswire
News headline image
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street
Via ACCESS Newswire
Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., “New Strategic Model &amp; Key Regulatory Milestones Provide Revenue Tailwind”
December 10, 2024, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Vivos Therapeutics, Inc. (NASDAQ: VVOS) titled, “New... 
Via TheNewswire.com
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage for Vivos CARE Oral Medical Devices
Via Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance for Pediatric Treatment of Sleep Apnea, Snoring
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational Update
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans Release of Q2 2024 Financial Results, Conference Call
Via Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Results of Seven-Month Provider-Based Marketing and Distribution Model Pilot
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Alliance, Private Equity Investment
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2024 Financial Report, Operational Update
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q1 2024 Results, Conference Call
Via Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Medicare Reimbursement Approval for CARE Oral Medical Devices in Proactive Interview
Via Investor Brand Network
Topics Product Recall
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Achieves Milestone with CARE Oral Medical Devices Gaining Approval for Medicare Reimbursement
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q4 and FY 2023 Results, Conference Call
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Exercise of Warrants for ~$4M
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Highlights Favorable Market Developments Creating New Opportunities
Via Investor Brand Network
Topics Product Recall
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Notes Key Market Developments Resulting in Growth Opportunities
Via Investor Brand Network
Topics Product Recall
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Record Numbers Following First-Ever FDA 510(k) Clearance of Proprietary Oral Medical Devices
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Host Pioneering Conference for Women in Medical, Dental Sectors
Via Investor Brand Network
News headline image
Black Swan: this small cap surged over 1000% last week
Vivos Therapeutics experienced a rare 'black swan' event, surging over 1000% in a single day following breaking news, here's how to look at VVOS stock now 
Via MarketBeat
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discussed ‘Breakthrough’ FDA Clearance in Proactive Interview
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces First-Ever FDA Clearance for Treatment of Severe Obstructive Sleep Apnea Using Oral Device
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Financial Report, Operational Update for Q3 2023
Via Investor Brand Network
Topics Supply Chain
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Closing of Million-Dollar Private Placement
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.